Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib

Megan L Goodall Laboratory of Systems Biology; Van Andel Research Institute; Grand Rapids, MI USA; Genetics Graduate Program; Michigan State University; East Lansing, MI USA

Tong Wang Translational Drug Development (TD2); Scottsdale, AZ USA

Katie R Martin Laboratory of Systems Biology; Van Andel Research Institute; Grand Rapids, MI USA

Matthew G Kortus Laboratory of Systems Biology; Van Andel Research Institute; Grand Rapids, MI USA

Audra L Kauffman Laboratory of Systems Biology; Van Andel Research Institute; Grand Rapids, MI USA

Jeffrey M Trent Translational Genomics Research Institute; Phoenix, AZ USA

Stephen Gately Translational Drug Development (TD2); Scottsdale, AZ USA

Jeffrey P MacKeigan Laboratory of Systems Biology; Van Andel Research Institute; Grand Rapids, MI USACorrespondence[email protected]

show all

Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib

Additional material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib

Additional material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date